4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Phase Ib/II open-label, multi-center study with a priming cycle of 4SC-202 to evaluate the
safety, tolerability and preliminary efficacy of combination treatment with 4SC-202 and
Pembrolizumab. A dose expansion cohort at the Recommended Phase Two Dose (RPTD) will be
added.
Adult patients with advanced (unresectable or metastatic) cutaneous melanoma primary
refractory or non-responding to anti-PD-1 therapy as most current systemic anti-cancer
therapy and for whom no standard therapy is available, will be enrolled. The last
administration of anti-PD-1 therapy must have been performed within 6 months prior to
screening.